Tisdale M - Search Results

1

HIV-1 reverse transcriptase (RT) genotype and susceptibility to RT inhibitors during abacavir monotherapy and combination therapy.

Miller V, Ait-Khaled M, Stone C, Griffin P, Mesogiti D, Cutrell A, Harrigan R, Staszewski S, Katlama C, Pearce G, Tisdale M. Miller V, et al. Among authors: tisdale m. AIDS. 2000 Jan 28;14(2):163-71. doi: 10.1097/00002030-200001280-00012. AIDS. 2000. PMID: 10708287 Clinical Trial.

2

M184V is associated with a low incidence of thymidine analogue mutations and low phenotypic resistance to zidovudine and stavudine.

Ait-Khaled M, Stone C, Amphlett G, Clotet B, Staszewski S, Katlama C, Tisdale M; CNA3002 International Study Team. Ait-Khaled M, et al. Among authors: tisdale m. AIDS. 2002 Aug 16;16(12):1686-9. doi: 10.1097/00002030-200208160-00017. AIDS. 2002. PMID: 12172093

3

HIV-1 reverse transcriptase and protease resistance mutations selected during 16-72 weeks of therapy in isolates from antiretroviral therapy-experienced patients receiving abacavir/efavirenz/amprenavir in the CNA2007 study.

Ait-Khaled M, Rakik A, Griffin P, Stone C, Richards N, Thomas D, Falloon J, Tisdale M; CNA2007 International Study Team. Ait-Khaled M, et al. Among authors: tisdale m. Antivir Ther. 2003 Apr;8(2):111-20. Antivir Ther. 2003. PMID: 12741623 Clinical Trial.

4

Human immunodeficiency virus type 1 reverse transcriptase mutation selection during in vitro exposure to tenofovir alone or combined with abacavir or lamivudine.

Stone C, Ait-Khaled M, Craig C, Griffin P, Tisdale M. Stone C, et al. Among authors: tisdale m. Antimicrob Agents Chemother. 2004 Apr;48(4):1413-5. doi: 10.1128/AAC.48.4.1413-1415.2004. Antimicrob Agents Chemother. 2004. PMID: 15047556 Free PMC article.

5

Mutations in HIV-1 reverse transcriptase during therapy with abacavir, lamivudine and zidovudine in HIV-1-infected adults with no prior antiretroviral therapy.

Ait-Khaled M, Rakik A, Griffin P, Cutrell A, Fischl MA, Clumeck N, Greenberg SB, Rubio R, Peters BS, Pulido F, Gould J, Pearce G, Spreen W, Tisdale M, Lafon S; CNA3003 International Study Team. Ait-Khaled M, et al. Among authors: tisdale m. Antivir Ther. 2002 Mar;7(1):43-51. Antivir Ther. 2002. PMID: 12008787 Clinical Trial.

6

Resistance profile of the human immunodeficiency virus type 1 reverse transcriptase inhibitor abacavir (1592U89) after monotherapy and combination therapy. CNA2001 Investigative Group.

Harrigan PR, Stone C, Griffin P, Nájera I, Bloor S, Kemp S, Tisdale M, Larder B. Harrigan PR, et al. Among authors: tisdale m. J Infect Dis. 2000 Mar;181(3):912-20. doi: 10.1086/315317. J Infect Dis. 2000. PMID: 10720512

7

A novel genotype encoding a single amino acid insertion and five other substitutions between residues 64 and 74 of the HIV-1 reverse transcriptase confers high-level cross-resistance to nucleoside reverse transcriptase inhibitors. Abacavir CNA2007 International Study Group.

Rakik A, Ait-Khaled M, Griffin P, Thomas TA, Tisdale M, Kleim JP. Rakik A, et al. Among authors: tisdale m. J Acquir Immune Defic Syndr. 1999 Oct 1;22(2):139-45. doi: 10.1097/00126334-199910010-00005. J Acquir Immune Defic Syndr. 1999. PMID: 10843527

8

Absence of zidovudine resistance in antiretroviral-naive patients following zidovudine/lamivudine/protease inhibitor combination therapy: virological evaluation of the AVANTI 2 and AVANTI 3 studies.

Maguire M, Gartland M, Moore S, Hill A, Tisdale M, Harrigan R, Kleim JP. Maguire M, et al. Among authors: tisdale m. AIDS. 2000 Jun 16;14(9):1195-201. doi: 10.1097/00002030-200006160-00017. AIDS. 2000. PMID: 10894284 Clinical Trial.

9

Effect of concurrent zidovudine use on the resistance pathway selected by abacavir-containing regimens.

Lanier ER, Givens N, Stone C, Griffin P, Gibb D, Walker S, Tisdale M, Irlbeck D, Underwood M, St Clair M, Ait-Khaled M. Lanier ER, et al. Among authors: tisdale m. HIV Med. 2004 Nov;5(6):394-9. doi: 10.1111/j.1468-1293.2004.00243.x. HIV Med. 2004. PMID: 15544690 Free article.

10

Phenotypic impact of HIV reverse transcriptase M184I/V mutations in combination with single thymidine analog mutations on nucleoside reverse transcriptase inhibitor resistance.

Ross L, Parkin N, Chappey C, Fisher R, Clair MS, Bates M, Tisdale M, Lanier ER. Ross L, et al. Among authors: tisdale m. AIDS. 2004 Aug 20;18(12):1691-6. doi: 10.1097/01.aids.0000131355.44834.e4. AIDS. 2004. PMID: 15280780

Save citations to file

Email citations

Send citations to clipboard

Add to Collections

Add to My Bibliography

Create a file for external citation management software

Your saved search

Your RSS Feed

My NCBI Filters

Text availability

Article attribute

Article type

Publication date

335 results

Search Page